This is a preview of subscription content, log in via an institution to check access.
References
San-Juan-Rodriguez A, et al. Trends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D. JAMA Neurology : 26 Aug 2019. Available from: URL: http://doi.org/10.1001/jamaneurol.2019.2711
Hartung DM, et al. Addressing the Rising Prices of Disease-Modifying Therapies for Multiple Sclerosis. JAMA Neurology : 26 Aug 2019. Available from: URL: http://doi.org/10.1001/jamaneurol.2019.2445
Rights and permissions
About this article
Cite this article
Dramatic price rises of MS therapies in the US big concern. PharmacoEcon Outcomes News 836, 10 (2019). https://doi.org/10.1007/s40274-019-6183-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6183-0